F-star Therapeutics Inks License Deal With Takeda To Develop Bispecific Antibody
(RTTNews) - Biopharmaceutical company F-star Therapeutics, Inc. (FSTX), operating through its subsidiary, F-star Therapeutics Ltd., announced Wednesday that it has entered into a license agreement with Japan's Takeda Pharmaceutical Co. Ltd. (TAK) to develop a bispecific antibody.
Under the terms of the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing license to research, develop, and commercialize a bispecific antibody against an immuno-oncology target using F-star's proprietary Fcab and mAb2 platforms.
Takeda will be responsible for all research, development, and commercialization activities under the agreement. F-star will receive an upfront license fee of $1 million.
F-star is also eligible to receive future development and commercialization milestone payments up to approximately $40 million over the course of the agreement if all milestones are achieved, plus single-digit percentage royalties on annual net sales.
U.S. Dollar Ticks Lower As Investors Monitor Developments In Middle East
TSX Drops Nearly 2.5%; Materials, Tech Stocks Down Sharply
Swiss Market Ends Modestly Higher
Major European Markets End Mixed As Investors React To Earnings, Economic Data
Chicago Business Barometer Pulls Back But Still Indicates Growth In October
Colgate-Palmolive Q3 Results Rise, Lifts FY26 Base Business EPS View; Stock Gains
Bay Street Likely To Open Notably Lower
